This content is not available in your region

GSK reports positive data from trial of endometrial cancer drug

Access to the comments Comments
GSK reports positive data from trial of endometrial cancer drug
FILE PHOTO: GlaxoSmithKline's production building is seen in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS   -   Copyright  POOL(Reuters)
Text size Aa Aa

(Reuters) – GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

Results from the GARNET study showed the drug elicited clinically meaningful and durable response rates when used to treat certain types of tumours, GSK said.

GSK said it would apply for marketing approval for dostarlimab in endometrial cancer at the end of 2019.

Dostarlimab was developed as part of a collaboration between Tesaro and AnaptysBio Inc.

GSK agreed to buy U.S. cancer specialist Tesaro for $5.1 billion (3.8 billion pounds) in December, giving it a marketed product for ovarian cancer, Zejula, which belongs to a promising class of medicines.

(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Bernard Orr)

euronews provides breaking news articles from reuters as a service to its readers, but does not edit the articles it publishes. Articles appear on for a limited time.